OGN:NYSE, Organon & Co.
OGN stock overview
Organon & Co. (OGN:NYSE) closed at $13.75 on October 23, 2026,
unchanged on the day.
The stock trades 0.6% below its 52-week high of $13.83
and 141.7% above its 52-week low of $5.69.
Over the past year, it gained 50.1%.
Organon & Co. is part of the Health Care sector.
Key figures
- Price
- $13.75
- Day change
- 0.00%
- Volume
- 1,051,943
- Average volume
- 2,639,514
- Market cap
- 3B+
- 52-week range
- $5.69 – $13.83
- 50-day average
- $13.73
- 200-day average
- $11.35
Price action over the past year
In 252 trading sessions since October 23, 2025, OGN closed higher on 124 days (49%).
Its best day was April 24, 2026 (+30.93%) and its worst was October 27, 2025 (-22.93%).
The stock moved 10% or more in a single session 6 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
OGN news
-
Oct 19, 2026:
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
-
Oct 16, 2026:
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
-
Oct 16, 2026:
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
-
Oct 14, 2026:
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
-
Oct 2, 2026:
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
-
Oct 1, 2026:
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
-
Oct 1, 2026:
Organon to Present New Real-World Analysis of VTAMA (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
-
Sep 28, 2026:
Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older
About Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
Similar stocks
Find more stocks like OGN with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.